Who are Gemcitabin/cisplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gemcitabine + cisplatin, GEMCITABINE CISPLATINE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gemcitabin-cisplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Gemcitabin/cisplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gemcitabin/cisplatin (Gemcitabin/cisplatin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (nucleoside analog + platinum alkylating agent). Area: Oncology.

phase 3 Chemotherapy combination (nucleoside analog + platinum alkylating agent) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gemcitabin/cisplatin (Gemcitabin/cisplatin) — Kuwait Cancer Control Center. Gemcitabine and cisplatin work together as a chemotherapy combination, with gemcitabine inhibiting ribonucleotide reductase to disrupt DNA synthesis and cisplatin forming DNA crosslinks to prevent replication.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Gemcitabin/cisplatin TARGET	Gemcitabin/cisplatin	Kuwait Cancer Control Center	phase 3	Chemotherapy combination (nucleoside analog + platinum alkylating agent)
Gemcitabine + cisplatin	Gemcitabine + cisplatin	AstraZeneca	phase 3	Chemotherapy combination (nucleoside analog + platinum alkylating agent)
GEMCITABINE CISPLATINE	GEMCITABINE CISPLATINE	University Hospital, Rouen	phase 3	Chemotherapy combination (nucleoside analog + platinum alkylating agent)	DNA synthesis machinery; DNA structure

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (nucleoside analog + platinum alkylating agent) class)

AstraZeneca · 1 drug in this class
Kuwait Cancer Control Center · 1 drug in this class
University Hospital, Rouen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gemcitabin/cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/gemcitabin-cisplatin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing